Osivelotor

DRUG4 trials

Sponsors

Pfizer

Conditions

HealthyLiver DiseasesSickle Cell Disease

Phase 1

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

CompletedNCT06340347

PfizerLiver Diseases

Start: 2024-04-30End: 2024-09-18Updated: 2025-01-10

A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults

Not yet recruitingNCT06507904

Start: 2026-09-22End: 2027-05-10Target: 52Updated: 2026-09-15

Phase 2

A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

RecruitingNCT05431088

PfizerSickle Cell Disease

Start: 2022-09-22End: 2032-12-31Target: 389Updated: 2026-08-18

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

TerminatedNCT05632354

PfizerSickle Cell Disease

Start: 2023-01-05End: 2025-02-13Updated: 2026-03-19

Related Papers

Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week phase 2, multicenter, open-label, dose-finding trial and extension study

Blood2025-11-03

Discovery of Osivelotor (GBT021601): A Potent, Next-Generation Sickle Hemoglobin Polymerization Inhibitor

ACS Medicinal Chemistry Letters2025-07-08

Discovery of Osivelotor (GBT021601): A Potent, Next-GenerationSickle Hemoglobin Polymerization Inhibitor

OPAL (Open@LaTrobe) (La Trobe University)2025-07-08

Preliminary Results from a Multicenter Phase 2/3 Study of Next-Generation HbS Polymerization Inhibitor GBT021601 for the Treatment of Patients with Sickle Cell Disease

Blood2023-11-0211 citations

Preliminary Pharmacodynamic Results from a Multicenter Phase 2/3 Study of Next-Generation HbS Polymerization Inhibitor GBT021601 for the Treatment of Patients with Sickle Cell Disease

Blood2023-11-022 citations